Notably, a phase I trial (NCT02106091) in patients with R/R NHL treated with another CD19 × CD3 BsAb, whose affinity for CD3 was 100-fold higher than that of blinatumomab, was discontinued due to a non-favorable risk/benefit profile [51]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.